Australian Operations
   
Include All CSL Behring Country Sites

Plasma Fractionation for New Zealand

CSL has been New Zealand’s national fractionator of plasma-derived therapies since 1962.

For further information visit the New Zealand Blood Service website.

Today, the New Zealand Government continues to choose CSL Behring as New Zealand’s national plasma fractionator. Regulated by Medsafe, a regulator held in high regard worldwide, CSL Behring and the New Zealand Blood Service ensure that the blood and plasma donations made voluntarily by people living in New Zealand continue to deliver the benefits that self-reliance provides – a sustainable, reliable and high quality source of plasma-derived therapies, developed to treat serious medical conditions including immunodeficiency disorders, a range of haematological and neurological disorders, haemophilia, haemolytic disease of the newborn and trauma. A range of products is also available to provide protection against infectious diseases including hepatitis B, tetanus and chickenpox.

Blood and plasma donated by New Zealand’s donors is fractionated into twelve plasma-derived therapies at CSL Behring's unique, purpose-built, chromatographic plasma fractionation facility, located at Broadmeadows in Victoria, Australia. For more information about these products, please refer to the table below.



A-Z of New Zealand Products

A   B   E   H   I   M   N   P   R   T   Z  
Product Name Subcategory Description

A

ALBUMEX® 20
Critical Care
Used when quantity of albumin in blood is low, for resuscitation in shock, in extensive burns, respiratory distress syndrome, blood purification and plasma exchange.
ALBUMEX®  4
Critical Care
Used when the blood volume is low, during heart-lung bypass surgery, and in plasma exchange.

B

BIOSTATE®
Coagulation Disorders
Used for patients with haemophilia A or von Willebrand disorder, in which there are reduced levels of factor VIII or von Willebrand factor respectively.

E

EVOGAM®
Immune Therapy
Used to treat patients who need replacement of antibodies which form part of our immune system.

H

Hepatitis B Immunoglobulin-VF
Immune Therapy
Used to help prevent hepatitis B infection in a person who comes into contact with suspected infected material.
Hizentra®
Immune Therapy
Used to treat patients who need replacement of antibodies. Antibodies are part of the immune system and help provide protection against infections.

I

INTRAGAM® P
Immune Therapy
Used to replace antibodies to help prevent infections and also used in the treatment of some autoimmune disorders.

M

MonoFIX®-VF
Coagulation Disorders
Used in patients with haemophilia B, in which there are reduced levels of Factor IX.

N

Normal Immunoglobulin-VF
Immune Therapy
Used for the replacement of antibodies to help prevent infections.

P

Privigen®
Immune Therapy
Used to treat patients who need replacement of antibodies and for the treatment of some autoimmune disorders.
PROTHROMBINEX®-VF
Coagulation Disorders
Used for the prevention and treatment of bleeding in patients with reduced levels of factor IX, II or X.

R

Rh(D) Immunoglobulin-VF
Immune Therapy
Used to prevent Haemolytic Disease of the Newborn.
RiaSTAP®
Coagulation Disorders
Used for treatment of acute bleeding episodes in patients with congenital fibrinogen deficiency.

T

Tetanus Immunoglobulin-VF IM
Immune Therapy
Used to help prevent tetanus in a person who has not recently been immunised against tetanus.
THROMBOTROL®-VF
Critical Care
Used for the treatment of patients with conditions relating to an inherited deficiency of antithrombin III.

Z

Zoster Immunoglobulin-VF
Immune Therapy
Used to help prevent chickenpox and shingles.